Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.
The study also unearthed a correlation between such changes and symptom-specific brain networks related to impaired cognition, sense of smell and fatigue.
After completing primary radiation therapy, patients in remission from cancers of the head and neck are better served by expectant management than routine imaging.
GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year.
The company plans to eventually provide professionals such as practice manages, schedulers, patient liaisons and revenue cycle teams with AI-enabled apps.